Literature DB >> 25151508

Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Karl-Josef Langen1, Jörg C Tonn, Michael Weller, Norbert Galldiks.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25151508     DOI： 10.1007/s11060-014-1594-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  13 in total

Review 1.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.

Authors:  Karl-Josef Langen; Kurt Hamacher; Matthias Weckesser; Frank Floeth; Gabriele Stoffels; Dagmar Bauer; Heinz H Coenen; Dirk Pauleit
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

2.  Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Karl-Josef Langen; Richard Holy; Michael Pinkawa; Gabriele Stoffels; Kay W Nolte; Hans J Kaiser; Christan P Filss; Gereon R Fink; Heinz H Coenen; Michael J Eble; Marc D Piroth
Journal:  J Nucl Med       Date:  2012-05-29       Impact factor: 10.057

3.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

4.  Clinical impact of amino acid PET in gliomas.

Authors:  Wolf-Dieter Heiss
Journal:  J Nucl Med       Date:  2014-07-08       Impact factor: 10.057

5.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Marion Rapp; Gabriele Stoffels; Gereon R Fink; Nadim J Shah; Heinz H Coenen; Michael Sabel; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-29       Impact factor: 9.236

6.  Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.

Authors:  Walter Rachinger; Claudia Goetz; Gabriele Pöpperl; Franz Josef Gildehaus; Friedrich Wilhelm Kreth; Markus Holtmannspötter; Jochen Herms; Walter Koch; Klaus Tatsch; Jörg-Christian Tonn
Journal:  Neurosurgery       Date:  2005-09       Impact factor: 4.654

7.  O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Dietmar Waitz; Gerd Tinkhauser; Herwig Kostron; Armin Muigg; Irene J Virgolini; Wolfgang Staffen; Eugen Trinka; Thaddäus Gotwald; Andreas H Jacobs; Guenther Stockhammer
Journal:  J Nucl Med       Date:  2011-06       Impact factor: 10.057

8.  O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.

Authors:  G Pöpperl; R Goldbrunner; F J Gildehaus; F W Kreth; P Tanner; M Holtmannspötter; J C Tonn; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-05       Impact factor: 9.236

9.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jochen Herms; Walter Koch; Jan H Mehrkens; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

Review 10.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130
View more
  5 in total

1.  Neuro-oncology: Amino acid PET for brain tumours - ready for the clinic?

Authors:  Karl-Josef Langen; Colin Watts
Journal:  Nat Rev Neurol       Date:  2016-06-10       Impact factor: 42.937

2.  PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors:  Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

3.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.

Authors:  Derek Richard Johnson; Chad Allan Glenn; Ramin Javan; Jeffrey James Olson
Journal:  J Neurooncol       Date:  2021-10-25       Impact factor: 4.130

4.  O-(2-[18F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres.

Authors:  Christian P Filss; Nathalie L Albert; Guido Böning; Elena Rota Kops; Bogdana Suchorska; Gabriele Stoffels; Norbert Galldiks; Nadim J Shah; Felix M Mottaghy; Peter Bartenstein; Jörg C Tonn; Karl-Josef Langen
Journal:  EJNMMI Res       Date:  2017-08-16       Impact factor: 3.138

5.  Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET.

Authors:  Keishi Horiguchi; Masahiko Tosaka; Tetsuya Higuchi; Yukiko Arisaka; Kenichi Sugawara; Junko Hirato; Hideaki Yokoo; Yoshito Tsushima; Yuhei Yoshimoto
Journal:  EJNMMI Res       Date:  2017-05-31       Impact factor: 3.138
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.